Mylan to Acquire Aspen's Thrombosis Business in the EU for ~ $758M
Shots:
- Mylan signed an agreement to acquire the related IP and commercialization rights of Aspen’s thrombosis business in the EU for $758.59M which include ~$311.08M as up front and ~$447.46 as deferred payment
- The acquired portfolio includes Arixtra- Fraxiparine- Mono-Embolex- and Orgaran which complements and bolster Mylan's complex injectables offering and presence in hospitals
- The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRIS upon the completion of Mylan's combination with Upjohn- anticipated to be close in Q4’20
Ref: PRNewswire | Image: Worldkings
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com